Compass Therapeutics
CMPX
76 hedge funds and large institutions have $177M invested in Compass Therapeutics in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 30 increasing their positions, 19 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
58% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 19
4% more funds holding
Funds holding: 73 → 76 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.13% less ownership
Funds ownership: 71.52% → 70.39% (-1.1%)
39% less capital invested
Capital invested by funds: $288M → $177M (-$111M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$1.09M |
| 2 |
Blackstone Inc
New York
|
+$467K |
| 3 |
Millennium Management
New York
|
+$354K |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$321K |
| 5 |
Goldman Sachs
New York
|
+$278K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.43M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.84M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$368K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
-$257K |
| 5 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
-$191K |
CMPX Hedge Fund Activity: Q3 2023 in Review
76 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q3 2023, worth a combined $177M — down 39% from $288M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CMPX positions and 5 closed out — a net gain of 3 holders — while 30 added to existing stakes and 19 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $1.09M. The largest seller was Fidelity Investments, cutting an estimated $2.43M.
- 76 institutional investors held Compass Therapeutics (CMPX) as of Q3 2023, up from 73 in Q2 2023.
- Funds reported $177M of Compass Therapeutics stock for Q3 2023, down 39% quarter-over-quarter.
- 8 funds opened new Compass Therapeutics positions in Q3 2023 and 5 closed out, a net change of +3 holders.
- The largest Compass Therapeutics buyer in Q3 2023 was Janus Henderson Group, an estimated $1.09M added.
- The largest Compass Therapeutics seller in Q3 2023 was Fidelity Investments, an estimated $2.43M sold.
Based on aggregated 13F filings for Q3 2023.